Skip navigation
Please use this identifier to cite or link to this item:
Authors: Ozturk, Seyma
Advisors: Sorensen, Erik
Contributors: Chemistry Department
Subjects: Organic chemistry
Issue Date: 2018
Publisher: Princeton, NJ : Princeton University
Abstract: Vancomycin, the first and founding member of the glycopeptide antibiotics, has been in clinical use since 1958 in the fight against bacterial infections. Due to its efficiency in treating multi drug-resistant bacteria, vancomycin has long been considered a drug of last resort. Antibiotic resistance has been recently observed to vancomycin like every other antibiotic that is currently on the market. Traditionally, synthetic tailoring has allowed us to repurpose ineffective antibiotics and reintroduce more effective derivatives back into the clinic, however, that is unfortunately not feasible with vancomycin because of its structural complexity. Herein, in collaboration with Seyedsayamdost group, we have developed a new platform for synthesizing vancomycin and useful vancomycin analogues, with the aim of repurposing this drug. In our approach, synthetic routes generate the monomeric amino acid units and the heptapeptide core of vancomycin, while the biosynthetic enzymes form three crosslinks and glycosidic bonds on the heptapeptide. The successful implementation of this chemoenzymatic approach, which combines the flexibility of chemical synthesis and the high selectivity of enzymatic synthesis, enables the preparation of vancomycin and the creation of new, perhaps improved, analogues in an efficient fashion.
Alternate format: The Mudd Manuscript Library retains one bound copy of each dissertation. Search for these copies in the library's main catalog:
Type of Material: Academic dissertations (Ph.D.)
Language: en
Appears in Collections:Chemistry

Files in This Item:
File Description SizeFormat 
Ozturk_princeton_0181D_12799.pdf10.24 MBAdobe PDFView/Download

Items in Dataspace are protected by copyright, with all rights reserved, unless otherwise indicated.